Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 6:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 545 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pulmonary Injury Clear all
Recruiting No phase listed Observational

Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients

NCT05866302
View directory record Official record
Conditions
Chronic Lung Disease, Hematopoietic Cell Transplantation, Graft Versus Host Disease
Interventions
Not listed
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
36 Months and older
Enrollment
375 participants
Timeline
2023 – 2028
U.S. locations
6
States / cities
Stanford, California • Atlanta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 7, 2026, 6:23 AM EDT
Completed Phase 1 Interventional

Montelukast in Very Low Birthweight Infants

NCT00492102
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Montelukast
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Days and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 7, 2026, 6:23 AM EDT
Not listed Phase 2 Interventional

Amifostine to Prevent Side Effects in Patients Who Are Receiving Chemotherapy and Radiation Therapy for Limited-Stage Small Cell Lung Cancer

NCT00003583
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity
Interventions
amifostine trihydrate, cisplatin, etoposide, radiation therapy
Drug · Radiation
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 7, 2026, 6:23 AM EDT
Recruiting No phase listed Observational

Lung Injury is One of the Primary Causes of Morbidity and Mortality in Critically Ill Patients. These Patients Will be Monitored for: 1) Immune Cell Activation 2) Blood-based Biomarkers. In Vitro Models Derived From These Samples Will be Treated With Novel Agent PIP-2 to Evaluate Its Efficacy.

NCT07125079
View directory record Official record
Conditions
ARDS (Acute Respiratory Distress Syndrome)
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 7, 2026, 6:23 AM EDT
Completed Phase 2 Interventional

Phase 2a MIB-626 vs. Placebo COVID-19

NCT05038488
View directory record Official record
Conditions
Covid19, Stage 1 Acute Kidney Injury
Interventions
MIB-626, Placebo, Home Treatment
Drug · Other
Lead sponsor
Metro International Biotech, LLC
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 7, 2026, 6:23 AM EDT
Withdrawn Phase 2 Interventional

Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite

NCT04401527
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome, Acute Respiratory Failure
Interventions
Sodium Nitrite, Normal Saline
Drug
Lead sponsor
Hope Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Tampa, Florida • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 7, 2026, 6:23 AM EDT
Completed Phase 2 Interventional Results available

Trial II of Lung Protection With Azithromycin in the Preterm Infant

NCT00319956
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
Hubert Ballard
Other
Eligibility
Up to 72 Hours
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 7, 2026, 6:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Electronic Nicotine Delivery Devices and Potential Progression to Acute Lung Injury

NCT05316727
View directory record Official record
Conditions
Acute Lung Injury, Pulmonary Injury, Electronic Cigarette Use, Electronic Cigarette Related Lung Injury
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 80 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 7, 2026, 6:23 AM EDT
Completed Phase 1 Interventional

Targeting Platelet-Leukocyte Aggregates in Pneumonia With Ticagrelor

NCT01883869
View directory record Official record
Conditions
Pneumonia, Community Acquired Pneumonia, Hospital Acquired Pneumonia, Acute Lung Injury
Interventions
ticagrelor, placebo
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 7, 2026, 6:23 AM EDT
Terminated Phase 2 Interventional Results available

PROactive Evaluation of Function to Avoid CardioToxicity

NCT03862131
View directory record Official record
Conditions
Cardiotoxicity, Breast Cancer, Lymphoma, Sarcoma, Leukemia, Myeloma, Lung Cancer
Interventions
MyoStrain®
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 7, 2026, 6:23 AM EDT
Completed Phase 1Phase 2 Interventional

Safety, Pk and Anti-inflammatory Effects of CC10 Protein in Premature Infants With Respiratory Distress Syndrome (RDS)

NCT01473264
View directory record Official record
Conditions
Respiratory Distress Syndrome in Premature Infant, Bronchopulmonary Dysplasia
Interventions
recombinant human CC10 (rhCC10), placebo
Drug
Lead sponsor
Clarassance, Inc.
Industry
Eligibility
24 Weeks to 29 Weeks
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
4
States / cities
Wilmington, Delaware • Baltimore, Maryland • Mineola, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 7, 2026, 6:23 AM EDT
Completed Phase 3 Interventional Results available

Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide

NCT00569530
View directory record Official record
Conditions
Respiratory Distress Syndrome of Prematurity (Surfactant Dysfunction), Bronchopulmonary Dysplasia
Interventions
Infasurf (ONY Inc.), Sham
Drug
Lead sponsor
Roberta Ballard
Other
Eligibility
7 Days to 14 Days
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
9
States / cities
Berkeley, California • Oakland, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 7, 2026, 6:23 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Feasibility of a Medical-Legal Partnership Model to Connect Coal Miners QuitAid

NCT07694492
View directory record Official record
Conditions
Tobacco Use Cessation, Tobacco Use Disorder, Nicotine Dependence, Smokeless Tobacco Use
Interventions
QuitAid (pharmacist-delivered MTM), Nicotine Replacement Therapy (NRT)
Behavioral · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 7, 2026, 6:23 AM EDT
Not listed Phase 2 Interventional

Airway Pressure Release Ventilation (APRV) Versus AC/VC Conventional Ventilation

NCT01339533
View directory record Official record
Conditions
Respiratory Failure, Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS)
Interventions
Mechanical Ventilation
Device
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Murray, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 7, 2026, 6:23 AM EDT
Active, not recruiting Phase 2 Interventional

A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants

NCT03253263
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity, Intraventricular Hemorrhage, Retinopathy of Prematurity (ROP)
Interventions
OHB-607
Drug
Lead sponsor
OHB Neonatology Ltd.
Industry
Eligibility
0 Hours to 24 Hours
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
24
States / cities
Little Rock, Arkansas • California City, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 7, 2026, 6:23 AM EDT
Terminated No phase listed Observational

Bronchial Mapping (GCC 1635)

NCT02745548
View directory record Official record
Conditions
Thoracic Cancer
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 7, 2026, 6:23 AM EDT
Completed No phase listed Observational

Study of the Pathobiology of Bronchopulmonary Dysplasia in Newborns

NCT00006058
View directory record Official record
Conditions
Respiratory Distress Syndrome, Bronchopulmonary Dysplasia
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 7, 2026, 6:23 AM EDT
Not listed Not applicable Interventional

Ultra-Low Tidal Volume Mechanical Ventilation in ARDS Through ECMO

NCT04832789
View directory record Official record
Conditions
ARDS
Interventions
Venovenous ECMO
Device
Lead sponsor
University of Toronto
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 7, 2026, 6:23 AM EDT
Completed Phase 3 Interventional

Early Versus Delayed Enteral Feeding to Treat People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN Study)

NCT00883948
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Minimal (Trophic) Feeding, Full Feeding
Behavioral
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
13 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
39
States / cities
Fresno, California • Sacramento, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Oct 7, 2026, 6:23 AM EDT
Active, not recruiting No phase listed Observational

COMPASSION S3 Post-Approval Study

NCT04860765
View directory record Official record
Conditions
Complex Congenital Heart Defect, Dysfunctional RVOT Conduit, Pulmonary Valve Insufficiency, Pulmonary Valve Degeneration, Pulmonary Valve; Obstruction
Interventions
SAPIEN 3 THV
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 7, 2026, 6:23 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Predicting the Need for Prolonged Respiratory Support in Neonates Delivered in a Lower-Level NICU Setting

NCT07344714
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn, Respiratory Distress Syndrome in Premature Infant, Transient Tachypnea of the Newborn, Meconium Aspiration Syndrome, Pneumonia Neonatal, Hyaline Membrane Disease, Pneumothorax, Respiratory Distress Neonatal
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
32 Weeks to 41 Weeks
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 7, 2026, 6:23 AM EDT
Active, not recruiting Not applicable Interventional

Implementation of Neuro Lung Protective Ventilation

NCT03243539
View directory record Official record
Conditions
Acute Brain Injury, Traumatic Brain Injury, Intracerebral Hemorrhage, Stroke, Cerebral Edema, Anoxic Brain Injury
Interventions
Lung Protective Ventilation
Procedure
Lead sponsor
Colin Grissom
Other
Eligibility
18 Years and older
Enrollment
728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 7, 2026, 6:23 AM EDT
Completed Phase 1 Interventional

Fluid Filled Lung Oxygenation Assistance Trial

NCT03041740
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Perfluorooctyl Bromide
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 6 Months
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 21, 2022 · Synced Oct 7, 2026, 6:23 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC)

NCT00618917
View directory record Official record
Conditions
Esophageal, Toxicity
Interventions
Manganese Superoxide Dismutase Plasmid Liposome, carboplatin, paclitaxel, Radiation Therapy
Genetic · Drug · Radiation
Lead sponsor
Joel Greenberger
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 12, 2021 · Synced Oct 7, 2026, 6:23 AM EDT